Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer: New Therapeutic Prospects
Highlights
- Bevacizumab plus erlotinib produced a 72% response rate in HLRCC-associated papillary renal-cell carcinoma, with median progression-free survival of 21.1 months.
- In sporadic papillary renal-cell carcinoma, response rate was 35%, with median progression-free survival of 8.9 months.
- Common side effects included rash, diarrhea, and proteinuria; grade 3 or higher adverse events were mostly hypertension and proteinuria.
- This combination represents the first regimen to demonstrate substantial efficacy in advanced HLRCC-related papillary renal-cell carcinoma.
Clinical Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.